MyPal-Child study protocol: an observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients

Marcel Meyerheim, Christina Karamanidou, Sheila Payne, Tina Garani-Papadatos, Annette Sander, Julia Downing, Kostas Stamatopoulos, J Ling, Cathy Payne, Lydia Scarfò, Petr Lokaj, Christos Maramis, Norbert Graf, Marcel Meyerheim, Christina Karamanidou, Sheila Payne, Tina Garani-Papadatos, Annette Sander, Julia Downing, Kostas Stamatopoulos, J Ling, Cathy Payne, Lydia Scarfò, Petr Lokaj, Christos Maramis, Norbert Graf

Abstract

Introduction: Electronic patient-reported outcomes (ePROs) have tremendous potential to optimise palliative and supportive care for children with cancer, their families and healthcare providers. Particularly, these children and their families are subjected to multiple strains caused by the disease and its treatment. The MyPal digital health platform is designed to address these complex demands by offering pursuant ePRO-based functionalities via two mobile applications, one developed for children and the other for their parents.

Methods and analysis: In this observational prospective feasibility study, 100 paediatric oncology patients aged between 6 and 17 years and at least one of their parents/legal guardians will be recruited at three clinical sites in two European countries (Germany and Czech Republic). They will use the mobile applications which are part of the novel digital health platform. During a 6-month study period, participants will complete various ePROs via the applications addressing quality of life, satisfaction with care and impact of the disease on the family at monthly intervals. Additionally, priority-based symptom reporting is integrated into a serious game for children. Outcomes that will be assessed concern the feasibility and the evaluation of the newly designed digital health platform to contribute to the evidence base of clinical ePRO use in paediatric oncology and palliative care process.

Ethics and dissemination: The MyPal-Child study obtained ethical approval from the Ethics Committee responsible for the University of Saarland, that is, the Ärztekammer des Saarlandes, the Ethics Committee of the Medical School Hannover and the Ethics Committee of the University of Brno. Study results will be disseminated through scientific publications, presentations at international conferences, congresses and a final report to the European Commission. General publicly accessible information can be found on the project website (www.mypal-project.eu) and social media.

Trial registration numbers: U1111-1251-0043, DRKS00021458, NCT04381221.

Keywords: health informatics; paediatric oncology; paediatric palliative care.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Patient-specific study enrolment schema of MyPal4Kids. ePROS, electronic patient-reported outcomes.
Figure 2
Figure 2
Software and hardware modules of the MyPal digital health platform. The MyPal Child and carer APP are useable via various types of mobile devices. The user of the MyPal carer APP are the parents/legal guardians involved in the study. Healthcare professionals can use the MyPal carer APP as well to report as proxy for the child.
Figure 3
Figure 3
(A) A screenshot of the gamified symptom questionnaire as part of the MyPal Child app. (B) Screenshots taken of the MyPal carer APP depicting the PATSAT C-33 questionnaire with instruction screen, selection of patient setting screen and one sample question screen.
Figure 4
Figure 4
Symptoms reported by study participants can be visualised in the MyPal web-based app for HCPs to be reviewed according to adjustable settings.

References

    1. World Health Organization . Cancer pain relief and palliative care in children. World Health Organization, 1998.
    1. Hoerger M, Greer JA, Jackson VA, et al. . Defining the elements of early palliative care that are associated with patient-reported outcomes and the delivery of end-of-life care. J Clin Oncol 2018;36:1096–102. 10.1200/JCO.2017.75.6676
    1. Leahy AB, Feudtner C, Basch E. Symptom monitoring in pediatric oncology using patient-reported outcomes: why, how, and where next. Patient 2018;11:147–53. 10.1007/s40271-017-0279-z
    1. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health . Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79. 10.1186/1477-7525-4-79
    1. Eliasen A, Abildtoft MK, Krogh NS, et al. . Smartphone APP to Self-Monitor nausea during pediatric chemotherapy treatment: User-Centered design process. JMIR Mhealth Uhealth 2020;8:e18564. 10.2196/18564
    1. LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. Nat Rev Clin Oncol 2017;14:763–72. 10.1038/nrclinonc.2017.153
    1. Downing J, Namisango E, Harding R. Outcome measurement in paediatric palliative care: lessons from the past and future developments. Annals of palliative medicine 2018.
    1. Bausewein C, Daveson BA, Currow DC. Eapc white paper on outcome measurement in palliative care: improving practice, attaining outcomes and delivering quality services – recommendations from the European association for palliative care (EAPC) Task force on outcome measurement. Palliative Medicine 2015.
    1. Maguire R, Fox PA, McCann L, et al. . The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer. BMJ Open 2017;7:e015016. 10.1136/bmjopen-2016-015016
    1. Peres SC, Pham T, Phillips R. Validation of the system usability scale (Sus). Proc Hum Factors Ergon Soc Annu Meet 2013;57:192–6. 10.1177/1541931213571043
    1. Jupp JCY, Sultani H, Cooper CA, et al. . Evaluation of mobile phone applications to support medication adherence and symptom management in oncology patients. Pediatr Blood Cancer 2018;65:e27278. 10.1002/pbc.27278
    1. Tomlinson D, Hyslop S, Stein E, et al. . Development of mini-SSPedi for children 4-7 years of age receiving cancer treatments. BMC Cancer 2019;19:32. 10.1186/s12885-018-5210-z
    1. Dupuis LL, Johnston DL, Baggott C, et al. . Validation of the symptom screening in pediatrics tool in children receiving cancer treatments. In: Journal of the National Cancer Institute 2018;110:661–8. 10.1093/jnci/djx250
    1. Varni JW, Burwinkle TM, Katz ER, et al. . The PedsQL in pediatric cancer: reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer 2002;94:2090–106. 10.1002/cncr.10428
    1. Robert RS, Paxton RJ, Palla SL, et al. . Feasibility, reliability, and validity of the pediatric quality of life inventory ™ generic core scales, cancer module, and multidimensional fatigue scale in long-term adult survivors of pediatric cancer. Pediatr Blood Cancer 2012;59:703–7. 10.1002/pbc.24099
    1. Stein RE, Riessman CK. The development of an impact-on-family scale: preliminary findings. Med Care 1980;18:465–72. 10.1097/00005650-198004000-00010
    1. EuroQol Research Foundation . EQ-5D-3L user guide, 2018. Available: [Accessed October 1, 2019].
    1. Brédart A, Anota A, Young T, et al. . Phase III study of the European organisation for research and treatment of cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7). Eur J Cancer Care 2018;27:e12786. 10.1111/ecc.12786
    1. Brédart A, Beaudeau A, Young T, et al. . The European organization for research and treatment of cancer - satisfaction with cancer care questionnaire: revision and extended application development. Psychooncology 2017;26:400–4. 10.1002/pon.4127
    1. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing directive 95/46/EC (General data protection regulation) (text with EEA relevance) official Journal L119, 4.5 2016:1–88.
    1. Faul F, Erdfelder E, Lang A-G, et al. . G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175–91. 10.3758/BF03193146
    1. Fewtrell MS, Kennedy K, Singhal A, et al. . How much loss to follow-up is acceptable in long-term randomised trials and prospective studies? Arch Dis Child 2008;93:458–61. 10.1136/adc.2007.127316

Source: PubMed

3
S'abonner